TargetRho-associated protein kinase 1(Homo sapiens (Human))
Taipei Medical University
Curated by ChEMBL
Taipei Medical University
Curated by ChEMBL
Affinity DataKi: 0.200nMAssay Description:Inhibition of human ROCK1 expressed in baculovirus expression system by Kinase-Glo luminescent AssayMore data for this Ligand-Target Pair
TargetRho-associated protein kinase 2(Homo sapiens (Human))
Taipei Medical University
Curated by ChEMBL
Taipei Medical University
Curated by ChEMBL
Affinity DataKi: 0.200nMAssay Description:Inhibition of human ROCK2 expressed in baculovirus expression system by Kinase-Glo luminescent AssayMore data for this Ligand-Target Pair
Affinity DataKi: 0.970nMAssay Description:Binding affinity to A1 receptor (unknown origin)More data for this Ligand-Target Pair
Affinity DataKi: 1.20nMAssay Description:Binding affinity to A3 receptor (unknown origin)More data for this Ligand-Target Pair
TargetRho-associated protein kinase 2(Homo sapiens (Human))
Taipei Medical University
Curated by ChEMBL
Taipei Medical University
Curated by ChEMBL
Affinity DataKi: 4.20nMAssay Description:Inhibition of human ROCK2 by Kinase-Glo luminescent assayMore data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 2(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of N-terminal GST tagged recombinant human FGFR2 (400 to 821 residues) expressed in an Sf9 infected baculovirus expression system using bi...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 4(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.90nMAssay Description:Inhibition of recombinant human FGFR4 (460 to 802 residues) using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.20nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
TargetRho-associated protein kinase 2(Homo sapiens (Human))
Taipei Medical University
Curated by ChEMBL
Taipei Medical University
Curated by ChEMBL
Affinity DataIC50: 3.60nMAssay Description:Inhibition of ROCK2 (unknown origin) using histone as substrate incubated for 20 mins in presence of [gamma32P]-ATP by liquid scintillation counter m...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5.20nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 5.5nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of CFD in 10% human serum assessed as reduction in alternate complement pathway-mediated hemolysis incubated for 1 hrMore data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6.10nMAssay Description:Inhibition of recombinant human FGFR3 V555M mutant using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrat...More data for this Ligand-Target Pair
Affinity DataIC50: 7.20nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of wild type partial length human FLT3 (V592 to Y969 residues) expressed in bacterial expression system using Ulight-p70S6K peptide substr...More data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 1(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8.10nMAssay Description:Inhibition of recombinant human FGFR1 using biotin-EQEDEPEGDYFEWLE-amide as substrate preincubated for 5 to 10 mins followed by substrate addition an...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of wild type partial length human TRKA (G475 to G790 residues) expressed in mammalian expression system using Ulight-p70S6K peptide substr...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of wild type partial length human FLT3 (V592 to Y969 residues) expressed in bacterial expression system using Ulight-p70S6K peptide substr...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
TargetDimer of Protein farnesyltransferase subunit beta(Homo sapiens (Human))
Schering-Plough Research Institute
Curated by ChEMBL
Schering-Plough Research Institute
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:In vitro inhibition of farnesyltransferase farnesylation of the H-ras oncogeneMore data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
TargetFibroblast growth factor receptor 3(Homo sapiens (Human))
Prelude Therapeutics
Curated by ChEMBL
Prelude Therapeutics
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of N-terminal His-Avi tagged recombinant human FGFR3 (447 to 761 residues) expressed in an Sf9 infected baculovirus expression system usin...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of TEL-FGFR3 in mouse BaF3 cells incubated for 125 mins by plate reader analysisMore data for this Ligand-Target Pair